Quant Multi Cap Fund

Quant Multi Cap Fund has delivered strong SIP XIRR across horizons, beating the category average at every period — 22.54% over 5Y versus 18.58% for the category and 21.38% over 10Y versus 18.01%. Against the NIFTY 50, the fund shows consistent alpha of 7.24% to 11.42% across long windows, with 10Y lump-sum CAGR of 17.11% versus the benchmark's 10.21%. Recent performance has softened, with 2025 returning -4.51% and 2026 YTD at 4.33%.

The fund exhibits a defensive return profile with beta below 1 across most periods (0.86-0.89 long-term) and downside capture of only 81-85% over 7-15Y, meaning it loses less than the index in falling markets. Ten drawdown events exceeding 10% indicate meaningful volatility, though the maximum drawdown of -0.36% with a 122-day recovery suggests the measured drawdown window was mild. Calmar ratios of 0.55-0.64 across horizons reflect reasonable risk-adjusted returns relative to drawdown experienced.

The 53-stock portfolio is led by Aurobindo Pharma at 9.49%, with Adani group companies (Adani Power, Adani Enterprises, Adani Green Energy) collectively forming a notable 13.6% cluster. Pharmaceuticals & Biotechnology is the largest sector at 20.4%, followed by Power at 12.1%, creating meaningful sector concentration. The remaining holdings are well diversified across auto components, consumer durables, entertainment, and capital markets.

The fund outperforms the category average SIP XIRR at every measured horizon, with the widest gaps at 5Y (22.54% vs 18.58%) and 12Y (19.15% vs 17.10%). Long-term calendar year returns show strong consistency in bull phases, including 67.32% in 2014 and 57.49% in 2021, though it has posted negative years in 2013, 2016, 2019, and 2025. Its persistent alpha versus NIFTY 50 across 7Y to 15Y windows supports a case for sustained stock-selection skill.

This fund suits investors seeking diversified multi-cap exposure with a long-term horizon of at least 5-7 years, given its strongest returns over 5Y+ periods. It is appropriate for moderate-to-high risk tolerance investors who can accept occasional negative calendar years and concentration in pharma and Adani group names. SIP investors benefit most, as the fund's XIRR consistently exceeds both category and benchmark averages.

• SIP XIRR beats category average at all horizons, including 22.54% over 5Y versus 18.58% for the category
• Consistent alpha versus NIFTY 50 of 7.24% to 11.42% across 7Y-15Y windows with low downside capture of 81-85%
• Low expense ratio of 0.74% for a multi-cap actively managed fund

• Sector concentration with Pharmaceuticals at 20.4% and Power at 12.1%, plus a 13.6% combined exposure to Adani group companies
• Recent momentum has weakened, with -4.51% in 2025 and only 4.33% in 2026 YTD, and 10 drawdown events exceeding 10% indicate periodic volatility